Can MR-proADM improve prediction of outcome in acutely ill patients?
Research type
Research Study
Full title
The clinical utility of a risk assessment tool combining NEWS (National Early Warning Score) and mid-regional pro-adrenomedullin (MR-proADM) for the disposition planning of acutely ill patients
IRAS ID
169785
Contact name
Ashley Price
Contact email
Sponsor organisation
Newcastle upon Tyne Hospitals NHS Foundation Trust
Duration of Study in the UK
0 years, 4 months, 30 days
Research summary
When a patient is admitted to hospital as an emergency, simple “early warning scores” (EWS) are used with the aim of identifying early deterioration in the patient’s condition, such that appropriate treatment can be started as early as possible. This system is not failsafe however, and any test that added to (or replaced) EWS by providing quicker, earlier and more accurate ways of predicting deterioration would be of huge value to healthcare services. One rapid blood test that potentially fulfills these criteria measures concentrations of MR-proADM (a protein produced in the early phases of acute illness). MR-proADM has shown great promise in predicting outcomes in specific medical conditions.
The aim of this study is therefore to test whether MR-proADM could improve the capacity of the NEWS score (widely used in UK hospitals) to predict outcomes early in the course of hospital admission. The study simply involves adding the MR-proADM test to tests performed on blood already taken from patients on admission (ie there are no additional blood tests required) and observing the outcome of patients’ on the medical admissions unit at the Royal Victoria Infirmary, Newcastle upon Tyne. The accuracy of either a) a change in NEWS or b) MR-proADM for predicting patient outcomes will be calculated. Outcomes will include which ward they transferred to, time to discharge, mortality, whether discharged patients were re-admitted, and cost to the NHS).
Should the study demonstrate that MR-proADM could potentially have improved care in this patient cohort, it will pave the way for future studies testing whether MR-proADM can actually improve patient pathways and whether clinical staff would be accepting of such a test in practice.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
15/NE/0120
Date of REC Opinion
21 May 2015
REC opinion
Further Information Favourable Opinion